PS
SRPT icon

Principal Securities’s Sarepta Therapeutics SRPT Stock Holding History

Principal Securities’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-478
Closed -$9.21K – 3235
2025
Q3 		$9.21K Sell
478
-9
-2% -$160 ﹤0.01% 2750
2025
Q2 		$8.33K Buy
487
+266
+120% +$11.3K ﹤0.01% 2690
2025
Q1 		$26.9K Hold
221
– – ﹤0.01% 2045
2024
Q4 		$26.9K Sell
221
-4
-2% -$490 ﹤0.01% 2041
2024
Q3 		$28.1K Sell
225
-921
-80% -$127K ﹤0.01% 1953
2024
Q2 		$181K Buy
1,146
+872
+318% +$112K 0.01% 1072
2024
Q1 		$35.5K Hold
274
– – ﹤0.01% 1725
2023
Q4 		$26.4K Buy
+274
New +$26.3K ﹤0.01% 1778

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Principal Securities's SRPT Position: Q4 2025 in Review

Principal Securities sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 478 shares — an estimated $9.21K sold.

Principal Securities first reported a position in SRPT in Q4 2023 and held it in 8 quarters. The position peaked at $181K in Q2 2024. 344 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Principal Securities reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 478 Sarepta Therapeutics shares in Q4 2025, an estimated $9.21K.
  • Principal Securities first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Sarepta Therapeutics position peaked at $181K in Q2 2024.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.